News
IRON
71.72
-0.08%
-0.06
Weekly Report: what happened at IRON last week (0413-0417)?
Weekly Report · 10h ago
Noteworthy Friday Option Activity: NN, MBI, IRON
NASDAQ · 3d ago
Disc Medicine CMO William Jacob Savage disposes of $379,087 common shares
PUBT · 4d ago
Disc Medicine CFO Jean M. Franchi disposes of USD 460,996 common shares
PUBT · 4d ago
Weekly Report: what happened at IRON last week (0406-0410)?
Weekly Report · 04/13 09:11
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
PR Newswire · 04/09 21:36
Weekly Report: what happened at IRON last week (0330-0403)?
Weekly Report · 04/06 09:11
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
PR Newswire · 03/30 21:41
3 Best Stocks to Buy Today, 3/30/2026, According to Top Analysts
TipRanks · 03/30 13:05
Analysts Are Bullish on These Healthcare Stocks: Disc Medicine (IRON), Alumis Inc. (ALMS)
TipRanks · 03/30 11:20
Weekly Report: what happened at IRON last week (0323-0327)?
Weekly Report · 03/30 09:11
Wedbush Keeps Their Buy Rating on Disc Medicine (IRON)
TipRanks · 03/27 12:55
Disc Medicine completes Phase 3 APOLLO enrollment for bitopertin in EPP; trial size grows to 183 participants
Reuters · 03/26 20:44
Disc Medicine completes enrollment in APOLLO trial
TipRanks · 03/26 20:36
Disc Medicine Doses Last Patient In Pivotal Phase 3 APOLLO Study Of Bitopertin In Erythropoietic Protoporphyria
Benzinga · 03/26 20:32
DISC MEDICINE ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 3 APOLLO TRIAL OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA
Reuters · 03/26 20:30
DISC MEDICINE INC - APOLLO STUDY RESULTS EXPECTED IN Q4 2026
Reuters · 03/26 20:30
Weekly Report: what happened at IRON last week (0316-0320)?
Weekly Report · 03/23 09:10
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON
Barchart · 03/19 11:56
Weekly Report: what happened at IRON last week (0309-0313)?
Weekly Report · 03/16 09:10
More
Webull provides a variety of real-time IRON stock news. You can receive the latest news about Disc Medicine Inc through multiple platforms. This information may help you make smarter investment decisions.
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.